CYT-108
Phase 1- Indications
- Osteoarthritis
Company intelligence / Profile preview
Christie Medical Holdings' VeinViewer technology has been shown through clinical studies to increase both first stick success and patient satisfaction up to 100 percent. It has decreased unnecessary PICC line placements resulting in significant cost savings and vein preservation[10].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Christie Medical Holdings, Inc..